Share this page!

Harlan Krumholz Profile picture
Twitter logo
26 Dec, 4 tweets, 4 min read
Worth your time to take a look at @EdwardTufte new book: Seeing with Fresh Eyes: Meaning, Space, Data, Truth. He is a visionary warrior fighting for clarity in visual communication. Has always inspired me. edwardtufte.com/tufte/seeing-w…
@EdwardTufte From @EdwardTufte: “Conventions (We’ve always done it this way) enshired in leagacy code caused 50 years of content-hostile and reader-inconvenient data graphics in powerpoint, excel, and sophisticated data-analysis computer packages."
@EdwardTufte From @EdwardTufte: ‘Electronic health records seize ownership of medical information. Medical center business plans = own the data, own the patient.’ ‘Medical centers…intimidate patients to sign gag orders seizing ownership of all records.' @ePatientDave @TheLizArmy @myopennotes
@EdwardTufte @ePatientDave @TheLizArmy @myopennotes And this book is a joy to read… and imagine the pressure of how you format and organize your book about how the rest of the world is producing reader-hostile content - but he does it - and shows us by engaging our eyes and our heart. Now to see if I can employ the lessons.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Harlan Krumholz

Harlan Krumholz Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hmkyale

Harlan Krumholz Profile picture
4 Oct
Very interested in @Regeneron therapy…2 non-competing neutralizing antibodies…one to receptor binding domain of the spike protein and one to the ACE receptor. They reported out early interim results for treatment of symptomatic people. Other studies pending Image
@Regeneron Inclusion criteria for the @Regeneron study was adult, non-hospitalized, symptoms <=7d, SARS-CoV-2 confirmed, and not on other COVID-19 therapies. Mean age was 44y. Half male. 42% obese. 7% (20 people) in the reported group were 65y and older.
@Regeneron The antibody cocktail to SARS-CoV-2 had a greater reduction in viral load for those whose viral load was higher at baseline. Image
Read 9 tweets
Harlan Krumholz Profile picture
24 Sep
On the #COVID19 transparency front: JNJ has announced that they will share the Clinical Study Report and clinical trial participant data from their vaccine trial with researchers through @Yale Open Data Access (YODA) Project. @YaleMed @jsross119 @JNJNews jnj.com/coronavirus/le…
@Yale @YaleMed @jsross119 @JNJNews To provide context for the JNJ vaccine data sharing, @Yale YODA Project provides access to data to researchers w/ credible scientific proposal, agreement to report results, & commitment to protect participant privacy. Access decision is independent. yoda.yale.edu
@Yale @YaleMed @jsross119 @JNJNews To date, @Yale Open Data Access (YODA) Project has resulted in 42 submitted publications (31 published) based on JNJ participant-level data sharing. JNJ (Janssen) has committed to sharing data from all their drug and device trials through the YODA project. jnj.com/coronavirus/ou…
Read 6 tweets
Harlan Krumholz Profile picture
16 Sep
Worth reading, policymakers please take note. “Vaccine hesitancy: why American values matter” The argument for transparency and independent evaluation in vaccine evaluation. Brillant and needed piece by @davidbeier1747 @LawrenceGostin @TomBollyky biocentury.com/article/630376 Image
@davidbeier1747 @LawrenceGostin @TomBollyky The authors 'We argue that two concrete policy steps could go a long way toward establishing public trust in COVID-19 vaccines:full and public disclosure of all data used to justify approval of a vaccine, and the creation of an independent and bipartisan committee to advise FDA.'
@davidbeier1747 @LawrenceGostin @TomBollyky They go on to say: 'We believe that the last chapter of this steeplechase will be whether enough people get vaccinated. Current and expected levels of vaccine hesitancy are far too high to end the pandemic.’
Read 5 tweets
Harlan Krumholz Profile picture
5 Sep
I had an early look @TimothyDSnyder new book ‘Our Malady: Lessons in Liberty from a Hospital Diary’ A raw, honest, disturbing (and personal) look at American medicine & politics… and a challenge to do better. I highly recommend it. amazon.com/gp/product/B08… @CrownPublishing Image
@TimothyDSnyder @CrownPublishing The book has some tough observations about my institution, which I love even though we are imperfect, and my colleagues, who I admire even as we are imperfect. But I see this book not as blame of individuals, but a call for a system that better elevates our work and humanity.
@TimothyDSnyder @CrownPublishing The book wraps the experience of a patient (the author) in the erudite perspective of one of our leading historians. We in healthcare almost always benefit from seeing through the patients’ eyes. He challenges us to elevate the system. And address what leads to disparities.
Read 4 tweets
Harlan Krumholz Profile picture
31 Aug
Fascinating and important paper by @VirusesImmunity and team on sex differences in immune response to COVID-19. nature.com/articles/s4158… @YaleMed
@VirusesImmunity @YaleMed What they found… “First... levels of several important proinflammatory innate immune chemokines and cytokines such as IL-8, IL-18 (at base-line), and CCL5 (longitudinal analysis) were higher in male patients, which correlated with higher non-classical monocytes (at baseline)."
@VirusesImmunity @YaleMed "Second, [they] observed a more robust T cell response among female patients compared to male patients at baseline. In particular, activated CD8 T cells were significantly elevated only in female patients but not in male patients over healthy volunteers."
Read 4 tweets
Harlan Krumholz Profile picture
30 Aug
The SGLT2 inhibitors are now officially not ‘diabetes’ medications, but also drugs capable of risk reduction for people with heart failure and reduced systolic function. And more than one option. All good news for patients. Now to ensure access. #ESCCongress #ESC2020 @TheLancet Image
@TheLancet The key thing about the meta-analysis of the SGLT2 inhibitors is that the primary endpoint was The primary endpoint was time to all-cause death. Not a composite. Not something needing adjudication. 13% reduction in allcause death (pooled HR 0·87, 95% CI 0·77–0·98; p=0·018).
@TheLancet The absolute difference in deaths was 1-2% range; but when you look across other outcomes, including hospitalizations, it is substantial. For adverse effects, interestingly, severe hypoglycaemic events was low, with
no increase in the active treatment groups in both trials.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @hmkyale has new unrolls!

Check out other threads from @hmkyale!

Read all threads by @hmkyale